Phone alerts could boost med adherence in schizophrenia
NCT ID NCT06474195
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether daily phone reminders can help people with schizophrenia or schizoaffective disorder remember to take their medication. 104 participants will receive repeated cues on their mobile phones for 30 days. The goal is to see if this improves medication adherence and prospective memory.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- cue-based intervention (daily phone reminders)
- What this could lead to
- If it works, this simple reminder strategy could help people with schizophrenia stick to their medication schedule, potentially improving their daily functioning.
- What could go wrong
- This is a small, early-stage study with only 104 participants. The benefit may be modest and might not apply to everyone with schizophrenia.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 104 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2024
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male and Female age 18 - 60 years * Diagnosed with Schizophrenia as per DSM V Criteria * Insight of grade 3 or more. * At least 10th standard level of education in the English language Exclusion Criteria: * Comorbid chronic medical illnesses. * Psychoactive substance use in harmful use pattern or in dependence pattern. * Co-existing neurodevelopmental disorders or learning disorders.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Schizophrenia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
St. John's Medical College and Hospital
Bengaluru, Karnataka, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug
- A shot every few weeks? new drug tested for schizophrenia